For the Inventor, By the Inventor

Enter assignee name

Takeda Pharmaceutical Company Limited

USPTO Granted Patents = 1,178

CIPO Patents = 125

EPO Patents = 573

Trademarks = 29

Forward Citations = 3,889

Loading Chart...

Loading Chart...

1,958 inventors (with patents filed for the assignee):

Tatsuki Koike (48 out of 48 patents)

Masato Yoshikawa (39 out of 83 patents)

Makoto Kamata (38 out of 39 patents)

4. Takahiro Sugimoto (33 out of 35 patents)

5. Jeffrey Alan Stafford (32 out of 141 patents)

6. Tsuneo Yasuma (31 out of 44 patents)

7. Minoru Nakamura (29 out of 65 patents)

8. Hiroki Sakamoto (29 out of 64 patents)

9. Tsuneo Oda (28 out of 41 patents)

10. Takuto Kojima (27 out of 27 patents)

11. Yasutaka Hoashi (26 out of 26 patents)

12. Masami Yamada (25 out of 25 patents)

13. Norihito Tokunaga (25 out of 25 patents)

14. Holger Monenschein (25 out of 44 patents)

15. Shinkichi Suzuki (25 out of 25 patents)

Core Competencies:

Pyrrolidine Compounds

Graphical User Interface

Plasma Kallikrein

FcRn-Binding Antibodies

Maribavir

Heterocyclic Compounds

CNS Delivery

Monoclonal Antibodies

Viral Inhibitors

Cryopreservation

TYK2 Inhibitors

Natural Killer Cells

1,178 patents: Sort by Forward Citations

1. 12492390 - Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof (2025-12-09),

2. D1103202 - Display screen or portion thereof with graphical user interface (2025-11-25),

3. 12479798 - Method for producing pyrrolidine compound (2025-11-25),

4. D1101762 - Display screen with a transitional graphical user interface (2025-11-11),

5. 12460016 - Plasma kallikrein binding proteins (2025-11-04),

6. 12454575 - Nucleic acids encoding FcRn-binding antibodies, pharmaceutical compositions thereof and methods of use thereof to make antibodies (2025-10-28),

7. 12448377 - Heterocyclic compound (2025-10-21),

8. 12447170 - Use of maribavir in treatment regimens (2025-10-21),

9. 12447169 - Maribavir isomers, compositions, methods of making and methods of using (2025-10-21),

10. D1098171 - Display screen or portion thereof with graphical user interface (2025-10-14),

11. D1098151 - Display screen with a graphical user interface (2025-10-14),

12. 12442824 - Assays for determining plasma kallikrein system biomarkers (2025-10-14),

13. 12441724 - Inhibitors of plasma kallikrein and uses thereof (2025-10-14),

14. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

15. 12433907 - Use of maribavir in treatment regimens (2025-10-07),

Takeda Pharmaceutical Company Limited is a global research-driven pharmaceutical company that focuses on the discovery, development, and delivery of innovative medicines to improve the lives of patients worldwide. With a history dating back more than 240 years, Takeda is committed to bringing better health and a brighter future to people everywhere. Headquartered in Tokyo, Japan, Takeda operates in over 80 countries and regions worldwide, employing approximately 50,000 people. Takeda's therapeutic areas span multiple medical fields, including oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

1,178 Patents

#23 in Osaka

#189 in Japan

#836 in the World

Takeda Pharmaceutical Company Limited

Forward Citations = 3,889

1,958 inventors:

Tatsuki Koike (48 out of 48 patents)

Masato Yoshikawa (39 out of 83 patents)

Makoto Kamata (38 out of 39 patents)

4. Takahiro Sugimoto (33 out of 35 patents)

5. Jeffrey Alan Stafford (32 out of 141 patents)

Please report any incorrect information to support@idiyas.com

Loading…